Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261415 | 0.85 | HPGD (0.57) | LMNAMEN1KMT2ATSHRPOLB | |
| SCHEMBL12802344 | 0.85 | L3MBTL1 (0.58) | LMNAMEN1KMT2ATSHRMAPT | |
| SCHEMBL4938661 | 0.84 | KDM4E (0.56) | LMNAMEN1KMT2ATSHRMAPT | |
| SCHEMBL5913849 | 0.83 | CYP3A4 (0.59) | LMNAMEN1KMT2ATSHRMAPT | |
| SCHEMBL5034363 | 0.83 | L3MBTL1 (0.48) | LMNAMEN1KMT2ATSHRMAPT | |
| SCHEMBL2454332 | 0.82 | TAAR1 (0.43) | L3MBTL1ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16041240 | 0.81 | ALDH1A1 (0.49) | LMNAMEN1KMT2ATSHRMAPT | |
| SCHEMBL6621894 | 0.81 | ACACB (0.52) | LMNAMEN1KMT2ATSHRMAPT | |
| SCHEMBL25342779 | 0.81 | LMNA (0.46) | LMNAMEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL2777352 | 0.81 | HTT (0.44) | MEN1KMT2ATSHRMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102834394-B | Bicyclic quinolone compounds, preparation and application thereof | KBP BIOSCIENCES CO LTD | 2015-03-25 | — | — | CN | disclosed |
| WO-2011124093-A1 | BICYCLIC QUINOLONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-10-13 | — | — | WO | disclosed |
| US-7375100-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375100-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375100-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1633715-B1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LTD (GB) | 2007-09-05 | — | — | EP | disclosed |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | LMNA 2688/4885MEN1 2743/4885KMT2A 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.